Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial

Key Points

This research aims to evaluate the efficacy and safety of autologous BCMA-directed mRNA CAR T-cell therapy in treating generalized myasthenia gravis.
Phase 2b randomized trial design
Use of autologous BCMA-directed mRNA CAR T-cells as intervention
Comparison with a placebo group
Efficacy observed in the treatment group compared to placebo
Safety profiles within acceptable limits
Significant improvement in symptoms reported in treated individuals

We only have this paper's title and publication details.

Phase 2b trial shows efficacy and safety of BCMA-directed mRNA CAR T-cell therapy in generalized myasthenia gravis, suggesting new treatment options.

77th American Academy of Neurology Annual Meeting, April 5-9, 2025, San Diego

No takes yet. Share an insight, caveat, or question.

Vu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share